Donia M. Moujalled

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

Medicine, Oncology, Pharmacology +11

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +14

Mitochondrial apoptosis is dispensable for NLRP3 inflammasome activation but non‐apoptotic caspase‐8 is required for inflammasome priming

Ramanjaneyulu Allam, Kate E. Lawlor, Eric Yu et al. · EMBO Reports · 2014 · 241 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Donia M. Moujalled, Giovanna Pomilio, Corina Ghiurau et al. · Leukemia · 2018 · 174 citations · Full text

Medicine, Oncology, Pharmacology +17

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

N-Y Nguyen, Donia M. Moujalled, David Segal et al. · Leukemia · 2017 · 153 citations · Full text

Medicine, Oncology, Pharmacology +13